Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity  by Unoki, Motoko & Nakamura, Yusuke
Methylation at CpG islands in intron 1 of EGR2 confers
enhancer-like activity
Motoko Unoki, Yusuke Nakamura
Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,
Tokyo 108-8639, Japan
Received 30 July 2003; revised 20 September 2003; accepted 20 September 2003
First published online 7 October 2003
Edited by Horst Feldmann
Abstract We previously demonstrated several lines of evidence
indicating that early growth response 2 (EGR2) functions as a
tumor suppressor, partly on the basis that its expression was
often decreased in human tumors and cancer cell lines. Here we
report a possible molecular mechanism to account for down-
regulation of EGR2 in tumor cells. Although no genetic muta-
tions in the gene or alterations in methylation status of its
promoter were detected, we found a high degree of methylation
at CpG islands in intron 1 of EGR2 in cell lines that were
expressing this gene at a high level. Moreover, reporter gene
experiments revealed that methylated intron 1 had somehow
conferred enhancer-like activity. The data imply the existence
of a previously unsuspected mechanism of gene expression reg-
ulation.
( 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Recently we published evidence that early growth response
2 (EGR2) functions as a tumor-suppressive mediator in the
PTEN signaling pathway [1,2]. Our previous reports included
¢ndings that expression of endogenous EGR2 was signi¢-
cantly low in primary ovarian cancers [2] as well as in various
cancer cell lines [3].
TheEgr2/Krox-20 gene was originally identi¢ed as a serum
response immediate-early gene [4]. Since Egr2 directly regu-
lates HoxB2 expression during hindbrain segmentation,
Egr2(3/3) mice display disruption of the segmentation and
die during the ¢rst 2 weeks after birth, and di¡erentiation of
Schwann cells in peripheral nervous system is also blocked at
an early stage [5^7]. In humans, defects of this gene are re-
sponsible for several hereditary neuronal diseases [8].
Here we report a molecular mechanism that might be in-
volved in the reduced expression of EGR2 that has been ob-
served in cancer cell lines derived from a variety of tissues.
Since we were unable to detect any EGR2 mutations in cells
expressing low levels of this gene, we examined its methylation
status in 16 representative cancer cell lines and found the
obvious tendency that intron 1 was hypermethylated in cells
that expressed high levels of EGR2, but hypomethylated in
lines showing decreased expression. When we examined tran-
scriptional activity of the respective unmethylated or methyl-
ated DNA segments, we observed enhancer-like activity in the
latter. Our data suggest a novel explanation for the regulation
mechanism of EGR2.
2. Materials and methods
2.1. Cell lines and normal tissue samples
Ishikawa3-H-12 was obtained from Tsukuba University (Tsukuba,
Japan). Eight cell lines of the HEC series were obtained from Kitasato
University (Sagamihara, Japan). AN3CA, KLE, MDAH2774, OV-
1063, SW626, NIH:OVCAR-3, SK-OV-3, SW480, LoVo, A172,
A549, H1299, LS174T, HT-29, DBTRG-05MG, U373MG, U87MG,
HCT116, HepG2, Huh7, Alexander, LNCap.FGC, and PC-3 were
obtained from the American Type Culture Collection (Manassas,
VA, USA). We obtained Sawano, HHUA, and HOUA-I from the
RIKEN Gene Bank (Tsukuba, Japan) and TYK-nu, LU99A, and
MKN74 from the Japanese Collection of Research Bioresources (To-
kyo, Japan). SNU423 and SNU475 came from the Korean cell line
bank. All cell lines used here were maintained as described previously
[3]. We obtained mRNA derived from normal tissue samples from BD
Bioscience Clontech (Palo Alto, CA, USA).
2.2. Real-time quantitative polymerase chain reaction (PCR)
Expression of EGR2 was analyzed quantitatively by TaqMan-PCR
assays [3]. Primer sequences were 5P-TCTTTCCCAATGCCGAAC-
TG-3P and 5P-GGAGATCCAACGACCTCTTCTCT-3P ; the probe
was 5P-TTGATCATGCCATCTCCGGCCACT-3P. The PCR prod-
ucts were measured according to the manufacturer’s protocol (Ap-
plied Biosystems, Foster City, CA, USA). GAPDH was used for nor-
malization (4310884E, Applied Biosystems).
2.3. Prediction of CpG islands in the EGR2 gene
CpG islands were predicted by means of a CPGPLOT program
(EMBOSS, http://bioweb.pasteur.fr/seqanal/interfaces/cpgplot.html).
2.4. Sodium bisul¢te sequencing
Genomic DNA was treated with sodium bisul¢te according to a
method described previously [9], with minor modi¢cations to improve
the e¡ectiveness of the reaction. Genomic DNA (3.2 Wg) was digested
overnight at 37‡C with 12 U each of AccI, RsaI, DraI, HincII, BstXI,
ClaI, EcoRV, MluI, NdeI, SphI, and XhoI (TaKaRa, Tokyo, Japan).
The DNA fragments were puri¢ed and dissolved in distilled water,
then denatured in 0.3 M NaOH at 42‡C for 30 min. A freshly pre-
pared solution containing sodium bisul¢te (Sigma, St. Louis, MO,
USA; ¢nal, 3.1 M, pH 5.0) and hydroquinone (Sigma; ¢nal 0.5
mM, pH 5.0) was added to each DNA and the solutions were incu-
bated at 55‡C for 18 h.
For DNA sequencing, the treated DNA fragments were ampli¢ed
using a PCR primer set designed for region IVS1+114 to +272 (for-
ward: 5P-GATTGTATTGGTTTTGAAGATTG-3P, reverse: 5P-CTC-
TTCCACCCCCATCCCT-3P). Thermal cycling was performed in 35
cycles of 94‡C for 30 s, 55‡C for 30 s, and 72‡C for 2 min. The PCR
products were cloned into pCR2.1 vector (Invitrogen, Carlsbad, CA,
USA), and 12 clones were sequenced for each cell line.
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2.5. Puri¢cation of proteins bound to methylated or unmethylated
EGR2 intron 1
Intron 1 was ampli¢ed by PCR using biotin-labeled forward primer
5P-(ATAACGCGT)ATACCATCCCAGGCTCAGTC-3P and non-la-
beled reverse primer 5P-(TATAGATCT)ATCCCAGTCAGTGCCGT-
GAT-3P. The ampli¢ed, biotinylated PCR product was methylated by
SssI (CpG methylase; New England Biolabs, Beverly, MA, USA)
under the conditions recommended by the manufacturer and its meth-
ylation status was con¢rmed by digestion with either a methylation-
sensitive restriction enzyme, HapII (TaKaRa) or an insensitive en-
zyme, MspI (TaKaRa). Unmethylated or methylated products were
mixed with streptavidin-Sepharose 4B (00560374, Zymed Laborato-
ries, South San Francisco, CA, USA) overnight at 4‡C. Binding was
con¢rmed by electrophoresis in 1% agarose gels and free intron 1
fragments were removed.
HCT116 cells were harvested from 20 dishes (150 mm) and their
nuclear extracts were prepared in a solution containing 20 mM
HEPES (pH 7.6), 20% glycerol, 100 mM NaCl, 1.5 mM MgCl2, 1.2
mM EDTA, 1 mM dithiothreitol, 0.1% NP40, and a protease inhib-
itor cocktail (Roche, Indianapolis, IN, USA). Appropriate competi-
tors (42 Wg of poly d[I-C], 20 Wg of intron 1/resin complex, and 60 Wg
of free pGL3 empty vector) were added to the extracts, mixed over-
night at 4‡C, and competitive proteins binding to the intron 1/resin
were removed by centrifugation. After 50 Wg of free competitive in-
tron 1 was mixed with the supernatant at 4‡C for 1 h, 16 Wg of either
methylated or unmethylated intron 1/resin complex was added and
mixed at 4‡C for 3 h. The protein/intron 1/resin complexes were
washed with the same bu¡er used for binding, and sample bu¡er
was added to adjust the total volume to 125 Wl. After the samples
were incubated in boiling water for 3 min and centrifuged, the super-
natants containing proteins that bound to methylated or unmethy-
lated intron 1 were separated by sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE).
2.6. Antibodies for Western blotting
Antibodies used here included mouse monoclonal antibody to hu-
man L-actin (AC-15; Sigma) and YY1 (sc-7341; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), goat polyclonal antibody to human
MBD1, MBD2, and MBD3 (respectively sc-9395, sc-12444, and sc-
9402; Santa Cruz), and rabbit polyclonal antibody to human MBD4
(sc-10753; Santa Cruz) and CTCF (06-917; Upstate, Lake Placid,
NY, USA).
2.7. Reporter gene assay using DNA fragments corresponding to intron
1 of the EGR2 gene
Reporter gene plasmids were constructed to represent various
lengths of nucleotide sequence in intron 1, each cloned into pGL3
promoter vector. The concentration of each plasmid clone was mea-
sured precisely, and DNAs were methylated. After heat inactivation
of the enzyme, the methylation status of each plasmid was examined
(see Section 2.5). Methylated and unmethylated constructs were sep-
arately co-transfected with pRL-TK (Promega, Madison, WI, USA)
into HCT116 cells by means of FuGENE16 Transfection Reagent
(Roche). Two days after transfection the reporter assay was carried
out using the Dual-Luciferase Reporter Assay system (Promega) ac-
cording to the manufacturer’s protocol.
3. Results
3.1. Expression of endogenous EGR2 in cancer cell lines
We determined the relative level of endogenous EGR2 ex-
pression in each of 39 cancer cell lines by quantitative reverse
transcriptase PCR, using the average expression level in 18
normal adult tissues as a baseline (Fig. 1). Expression of
this gene was lower than the normal average in almost all
of the cancer lines regardless of the organ of origin; the rel-
ative expression levels of 30 (77%) of the 39 cancer lines were
less than 0.1, while those in 20 of the 22 normal tissues were
higher than 0.1 (P6 0.0001: Fisher’s exact probability test).
3.2. Methylation status within EGR2 genomic sequences
We examined the gene and its promoter sequences for
screening somatic mutations or altered methylation in several
cell lines whose endogenous EGR2 expression was very low,
but observed no changes in any of the cells examined (data
not shown). However, by sequencing PCR products that were
ampli¢ed from genomic DNAs treated with sodium bisul¢te,
we found that a CpG island present in intron 1 (IVS+114 to
IVS+272; Fig. 2A,B) tended to be highly methylated in cell
lines where endogenous EGR2 expression level was relatively
high, i.e. where the relative expression by TaqMan assay was
s 0.1 (Fig. 2C). The same region was hypomethylated in cell
lines where relative expression was 6 0.1 (Fig. 2D). This cor-
relation was observed in 13 of the 16 cell lines examined in
this experiment; the three exceptional cases are documented in
Fig. 2E. The methylation status of 18 additional sites in a
CpG island that partially included exon 1 (+383 to
IVS1+114) and 31 sites in another CpG island (IVS1+531
to IVS1+790) revealed similar correlations in several represen-
tative cell lines examined (data not shown).
3.3. Is EGR2 intron 1 an insulator?
At ¢rst, we investigated whether intron 1 is an insulator
Fig. 1. Expression of endogenous EGR2 examined by TaqMan-PCR analysis using cDNAs from 39 cancer cell lines, four fetal tissues, and 18
normal adult tissues. The gene expression in the cancer lines was measured in three separate experiments, and the average was compared with
the average level of expression in the 18 adult tissues. The integrity of each template was controlled through ampli¢cation of GAPDH.
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Fig. 2. Predicted CpG islands within the EGR2 gene and methylation status of intron 1 in cancer cell lines. A: Map of predicted CpG islands.
Moving averages of %G+C (red) and Obs/Exp CpG (blue) were calculated using the CPGPLOT (EMBOSS) program. An area surrounded by
a vertical rectangle (IVS+114 to IVS+272) indicates the region described in B. B: Sequence of IVS+114 to IVS+272 in intron 1, with 15 CpG
dinucleotides indicated in boldface and underlined. The primer set indicated here was used for subsequent sodium bisul¢te sequencing analysis.
C: Hypermethylation in eight cell lines showing relatively high expression of EGR2. The ‘relative expression’ levels indicate results of TaqMan-
PCR experiments (see Fig. 1). D: Hypomethylation in intron 1 of EGR2 in ¢ve low-expression cell lines. E: Results in three exceptional cancer
cell lines.
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Fig. 3. Examination of binding a⁄nity of insulator-binding proteins to EGR2 intron 1. A: Schematic representation of the steps used to purify these proteins (see Section 3.3). B: Methyl-CpG-
binding proteins MBD1, MBD2, and MBD4 were detected only in the M lanes. ‘Input’ indicates lanes containing untreated nuclear extracts from HCT116 cells ; M and UM indicate lanes con-
taining methylated and unmethylated intron 1-binding proteins, respectively. C: L-Actin was removed by the protocol. D: MBD3, which has little speci¢city for methyl-CpG, bound equally to
unmethylated and methylated intronic sequences. E: Insulator-binding proteins CTCF and YY1 were detected in both lanes, at equal levels.
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that has an enhancer-inhibiting activity when the site is un-
methylated. So far, two insulator-binding proteins, CTCF and
YY1, have been isolated [10^13]. To investigate the possibility
that these proteins are associated with EGR2 expression, we
puri¢ed proteins that have binding a⁄nity for either methyl-
ated or unmethylated DNA (Fig. 3A). Each form of the 1.2-
kb intronic fragment was biotinylated during PCR ampli¢ca-
tion, and the SssI-treated or -untreated PCR product was
bound to streptavidin-Sepharose (resin). The fragment^resin
complex was mixed with nuclear extracts from HCT116 cells
and appropriate competitors ; proteins that bound to one or
the other DNA fragment were puri¢ed and separated by
SDS^PAGE. Fig. 3B^D shows results of experiments to val-
idate our protocol. Proteins known to have higher binding
a⁄nity for methyl-CpG, such as MBD1, MBD2, and
MBD4 [10], were detected only in the lanes containing pro-
teins bound to the methylated intronic sequence (Fig. 3B); no
L-actin, the negative control, was detected (Fig. 3C). MBD3,
which has no speci¢c binding a⁄nity for methyl-CpG [10],
bound equally to both the unmethylated and methylated in-
tron 1 sequences (Fig. 3D). Similar to MBD3, no speci¢c
binding was observed when we examined binding of two in-
sulator-binding proteins, CTCF [11^13] and YY1 [14], to in-
tron 1 (Fig. 3E).
3.4. Transcriptional activity of EGR2 intron 1
We then investigated unmethylated or methylated forms of
a 1.2-kb intronic segment that included two CpG islands by
means of a luciferase reporter assay. Reporter plasmids
(pGL3 promoter vector) with basal luciferase activity were
constructed to include various parts of this intronic DNA
segment (Fig. 4A), and enzymatically methylated. The meth-
ylation status was con¢rmed by digestion with two restriction
enzymes (Fig. 4B). Fig. 4C represents results of the assay
using HCT116 cells, which expressed EGR2 at a high level
and had a methylated intron 1, after transfection with SssI-
treated or -untreated plasmids. The methylated 1.2-kb intronic
fragment revealed the highest enhancer-like activity among
the fragments tested, but the corresponding unmethylated
form showed none at all. Either of the two 0.8-kb fragments
indicated in Fig. 4A as F+M and M+B, as well as each of the
three 0.4-kb fragments (F, M, and B), revealed respectively
40^60% and 20^35% enhancer-like activity compared with the
1.2-kb fragment.
4. Discussion
Endogenous expression of EGR2 in most of the cancer cell
lines we examined was less than in normal tissues. Somatic
Fig. 4. Enhancer-like activity of methylated intron 1 of EGR2. A: Construction of reporter gene plasmids representing various lengths of the
intron 1 sequence sub-cloned into pGL3 promoter vector. B: Con¢rmation of methylation status of the constructs using a methylation-sensitive
enzyme, HapII, or an insensitive enzyme, MspI. C: Each methylated or unmethylated construct was co-transfected with pRL-TK into HCT116
cells. Luciferase activity was measured 48 h later, and relative luciferase activity was calculated based on the activity of pGL3 PRM as 1.0 (re-
spectively unmethylated and methylated). Each data bar represents the mean of values from three separate experiments; error bar, S.D.
(Sche¡e¤’s F test).
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mutations or aberrant methylation in the EGR2 promoter
region were ruled out by sequencing and by analysis of meth-
ylation status of the promoter by sodium bisul¢te sequencing
(data not shown). However, CpG islands in intron 1 tended to
be highly methylated in cancer cell lines that were expressing
the gene abundantly, and to be hypomethylated in low-ex-
pressing lines. A few other reports have indicated that DNA
methylation does not always confer a gene-silencing e¡ect [11^
15]. Therefore on the basis of our ¢ndings we hypothesized
that (1) an insulator-binding protein such as CTCF [11^13]
and YY1 [14] may bind to the unmethyl-CpG and inhibit
enhancer activity; (2) a methylation-sensitive trans-suppres-
sive protein may down-regulate gene expression by binding
to the unmethylated intron; (3) a trans-activative methyl-
CpG-binding protein can bind to the methylated intron;
(4) a methylation-sensitive covering protein may inhibit the
binding of trans-activating factors to the unmethylated intron.
To investigate these possibilities, at ¢rst we examined the pos-
sibility that the EGR2 intron 1 was an insulator. We at-
tempted to purify proteins that bound speci¢cally to the meth-
ylated or unmethylated forms of intron 1 and examined
binding a⁄nity of CTCF and YY1 to intron 1. As a result,
they showed no speci¢c binding to the unmethylated intron
and were not likely to be the regulator of EGR2 expression.
MBD1, 2, and 4 used here as positive control are also con-
sidered to be possible candidates for the EGR2 expression
regulator. Since MBD2 forms complexes with a variety of
proteins and might have several functions [16^18], it is possi-
ble that other members of the MBD protein family would be
able to form complexes with unreported proteins and have
unknown functions to regulate the gene expression.
Although the possibility that intron 1 functions as an insu-
lator is not completely excluded, we suggest here other possi-
bilities by detecting transcriptional activity of unmethylated or
methylated fragments of the intron 1 sequence. A methylated
1.2-kb fragment showed the highest enhancer-like activity
among the regions tested, while the corresponding unmethy-
lated fragment lacked any such activity supporting the third
or fourth hypothesis. Since shorter fragments of intron 1 re-
vealed lower enhancer-like activity compared with the 1.2-kb
sequence, structural conformation is probably an important
feature of the transcription-enhancing activity we observed, in
conjunction with protein interactions involving this genomic
segment.
We think our data strongly imply the existence of a novel
mechanism that up-regulates gene expression through a com-
bination of intronic DNA methylation and structural confor-
mation. We think elucidation of this mechanism will not only
lead to an understanding of the EGR2 transcriptional regula-
tion mechanism but also shed light on the additional mecha-
nism of the gene expression regulation. Although promoter
regions of some tumor suppressors are reportedly hyperme-
thylated in cancer, genomic DNA from cancers generally
tends to be totally hypomethylated [19]. One of the keys to
solving this discrepancy might be found in the phenomenon
reported here.
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